Biogen announce they have stopped SCA3 clinical trial - Ataxia UK

Biogen announce they have stopped SCA3 clinical trial

Post Published: April 26, 2023

Ataxia UK were saddened to hear that Biogen have stopped their Phase I clinical trial for SCA3 therapeutic BIIB132 (MERA study). The trial was planned to be an international study, including a small number of people with SCA3 in the UK (read the original study announcement here). 

The decision to stop the trial was made after careful assessment of the nonclinical safety data, clinical pharmacodynamic data, and future development of BIIB132. 

Read the letter from Biogen Medical Director, Dr Rosalind Chuang here.

Subscribe To Our Newsletter

fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Scroll to Top